OncoLog, Volume 53, Number 11, November 2008 Page: Back Cover
8 p. : ill.View a full description of this periodical.
Extracted Text
The following text was automatically extracted from the image on this page using optical character recognition software:
OncoLog
The University of Texas
M. D. Anderson Cancer Center
Scientific Publications-18417501/1421
1515 Holcombe Blvd.
Houston, Texas 77030-4009
Address Service Requested
Clinical Trials in
Malignant Pleural MesotheliomaA Phase I Study of Induction Dasatinib
Therapy in Patients with Resectable
Malignant Pleural Mesothelioma (2006-
0935). Principal investigator (P1): Anne S.
Tsao, M.D. The goal of this trial is to evalu-
ate the effect of neoadjLvant dasatinib
against Src kinase Tyr4- 9, a biomarker
in MPM, and to correlate the levels of
this marker with survival and clinical
outcome. Dasatinib is an oral tyrosine
kinase inhibitor.
A Phase I Trial of Cisplatin, Pemetrexed,
and Imatinib Mesylate in Unresectable
or Metastatic Malignant Mesothelioma
(2005-0288). PI: Anne S. Tsao, M.D. In this
dose-determination study, investigators
hope that inhibition of p atelet-derived
growth factor receptors by imatinib mesy-
late (Gleevec) will increase tumor cell
uptake of the chemotherapeutic agents
cisplatin and pemetrexed (Alimta).A Multicenter Phase I/II Trial of Cisplatin,
Pemetrexed, and AZD2171 in Patients
with Unresectable Malignant Pleural
Mesothelioma (SWOG 0905). PI: Anne
S. Tsao, M.D. This Southwest Oncology
Group trial will test the oral tyrosine kinase
inhibitor AZD2171, which targets platelet-
derived growth factor receptors and vascu-
lar endothelial growth factor receptors, in
combination with the chemotherapeutic
agents cisplatin and pemetrexed.
(Activation pending.)
A Phase IB, Open-Label, Multicenter
Study to Investigate the Effect of Oral
LBH589 on Dextromethorphan, a CYP2D6
Substrate, and to Assess the Efficacy
and Safety of Oral LBH589 in Patients
with Advanced Solid Tumors 2007-0644).
PI: Vali Papadimitrakopoulou, M.D. LBH589
is a histone deactylase inhibitor that may
have some activity in mesothelioma. eMalignant Pleural Mesothelioma (Continued from page 3)
commonly used for palliation of tumor
bulk-removing tumor tissue reduces pain
and shortness of breath, which commonly
result from MPM. Other palliative options
include talc pleurodesis, in which an infu-
sion of talc into the pleura initiates a for-
eign-body reaction that closes off the cavi-
ty, preventing fluid accumulation; and the
installation of a permanent chest drain.
Still, Dr. Tsao stress_-s that such tech-
niques should be used as a last resort
and that careful staging and evaluation of
patients for potentially curative surgical
options should be made at facilities thatare familiar with treating MPM. "Many
people don't know that there are effective
therapies for MPM, and so some patients
who may benefit from curative treatment
don't receive those therapies," Dr. Tsao
said. "All MPM patients should know
about the best treatments that we have
available today and should consider
enrolling in clinical trials that hold the
best hope for the future." e
For more information, call Dr. Tsao
at 713-792-6363 or visit http://www.
mdanderson.org/diseases/mesothelioma.02008 The Unversty of Texas I )D Andersonceet Xcemr r2rm ed mnrecycled paper
OncoLog
The University of Texas
M. D. Anderson cancer center
President
Iln Nlei"lels"hn, Nl).
Provost and Executive Vice President
Raymond Dubo iM.D., Ph.D.
Senior Vice President for Academic Affairs
Stephen P'.Tniasoeie, Ph.D.
Director, Department of Scientific Publications
Wier J. Pagel
Managing Editor
lo Ie Lei
Assistant Managing Editors
Io nch ee Maiide Veecle
Contributing Editors
Melissa *. Bukett " Sinni Hosemann
Stephanie P. IDeining An NI. Suton
Design
Thce Very Idea'
Photography
IninsLeintine
Editorial Board
Michaelisch M I, Chair
Lyle ireen VicePCheir
ThrsenlRuee It,.D
Beverily Handy M.D.
Patrick Hwu, MD.
Charles Koller, M.D.
Maurte Markman, M.D.
Shreyaskumar Patel, M.D.
DaidschwartMD.
Rena SellinNIM.
Randal Weber, MD.
Christopher Wood, M.D.
Physicians: To refer a patient or learn more about
M. D. Anderson, please contact the Office of
Physician Relations at 713-792-2202, 1-800-252-0502,
or www.mdanderson.org/departments/physrelations.
Patients: To refer yourself to M. 1. Anderson or learn
more about our services, please call 1-877-632-6789
orr visit aurw.iedandersoin.uurg.
Pat q "estions at "rc eents aout OncoLog, please
e-mail scientificpuhlicanons@mdanderson.org or
call 713-792-3305. Current and previous issues
are available onlne i English and Spanish at
assi.itedandersiiteuiu/ontcoloay
Made possible ie pittblea if'it fromthr~e late
Mrs Harry C Wiess
N C Ip) CA Comprehensive aner
Cetrsgnted by the
ccc nl acrInttt8 OncoLog " November 2008
Search Inside
This issue can be searched. Note: Results may vary based on the legibility of text within the document.
Tools / Downloads
Get a copy of this page or view the extracted text.
Citing and Sharing
Basic information for referencing this web page. We also provide extended guidance on usage rights, references, copying or embedding.
Reference the current page of this Periodical.
University of Texas M.D. Anderson Cancer Center. OncoLog, Volume 53, Number 11, November 2008, periodical, November 2008; Houston, Texas. (https://texashistory.unt.edu/ark:/67531/metapth903079/m1/8/: accessed July 18, 2024), University of North Texas Libraries, The Portal to Texas History, https://texashistory.unt.edu.; crediting UNT Libraries Government Documents Department.